The prognostic value of CD8⁺ CTLs, CD163⁺ TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma

References

• Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140(9):971–979. doi:10.1182/blood.2020008377
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–1418. doi:10.1038/bjc.2011.357
   PubMed Web of Science ®Google Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418. doi:10.1200/JCO.2017.72.7602
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. doi:10.1182/blood.2022015851
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56(1):15. doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22(1):329–360. doi:10.1146/annurev.immunol.22.012703.104803
   PubMed Web of Science ®Google Scholar
• Venetz D, Ponzoni M, Schiraldi M, et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: t -cell infiltration and positioning of malignant B cells. Int J Cancer. 2010;127(10):2300–2312. doi:10.1002/ijc.25236
   PubMed Web of Science ®Google Scholar
• Sasayama T, Tanaka K, Mizowaki T, et al. Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in primary central nervous system lymphoma (PCNSL). Brain Pathol. 2016;26(4):479–487. doi:10.1111/bpa.12318
   PubMed Web of Science ®Google Scholar
• Yang R, Liao Y, Wang L, et al. Exosomes derived from M2b macrophages attenuate DSS-induced colitis. Front Immunol. 2019;10:2346. doi:10.3389/fimmu.2019.02346
   PubMed Web of Science ®Google Scholar
• Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci. 2008;13(13):453–461. doi:10.2741/2692
   PubMed Web of Science ®Google Scholar
• Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117(11):1583–1591. doi:10.1038/bjc.2017.356
   PubMed Web of Science ®Google Scholar
• Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 2012;4(4):376–389.
   PubMed Web of Science ®Google Scholar
• Wada N, Zaki MA, Hori Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka lymphoma study group. Histopathology. 2012;60(2):313–319. doi:10.1111/j.1365-2559.2011.04096.x
   PubMed Web of Science ®Google Scholar
• Carreras J, Kikuti YY, Hiraiwa S, et al. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma. Cancer Sci. 2022;113(1):334–348. doi:10.1111/cas.15179
   PubMed Web of Science ®Google Scholar
• Nam SJ, Go H, Paik JH, et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2014;55(11):2466–2476. doi:10.3109/10428194.2013.879713
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. doi:10.1073/pnas.192461099
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–3473. doi:10.1158/1078-0432.CCR-13-0855
   PubMed Web of Science ®Google Scholar
• Alame M, Pirel M, Costes-Martineau V, et al. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Virchows Arch. 2020;476(6):891–902. doi:10.1007/s00428-019-02695-6
   PubMed Web of Science ®Google Scholar
• Four M, Cacheux V, Tempier A, et al. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol. 2017;35(4):487–496. doi:10.1002/hon.2375
   PubMed Web of Science ®Google Scholar
• Abdulla M, Alexsson A, Sundström C, et al. PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. Acta Oncol. 2021;60(4):531–538. doi:10.1080/0284186X.2021.1881161
   PubMed Web of Science ®Google Scholar
• Marcelis L, Antoranz A, Delsupehe AM, et al. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother. 2020;69(9):1751–1766. doi:10.1007/s00262-020-02575-y
   PubMed Web of Science ®Google Scholar
• Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008;111(6):3200–3210. doi:10.1182/blood-2007-10-119099
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232–4244. doi:10.1158/1078-0432.CCR-10-2660
   PubMed Web of Science ®Google Scholar
• Lin CH, Kuo KT, Chuang SS, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res. 2006;12(4):1152–1156. doi:10.1158/1078-0432.CCR-05-1699
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043. doi:10.1200/JCO.2005.13.524
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Petty AJ, Yang Y. Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies. Cells. 2019;8(12):1526. doi:10.3390/cells8121526
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073. doi:10.1182/blood-2017-01-764209
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Ricken G, Widhalm G, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol. 2014;33(1):42–49. doi:10.5414/np300698
   PubMed Web of Science ®Google Scholar
• Riihijärvi S, Fiskvik I, Taskinen M, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100(2):238–245. doi:10.3324/haematol.2014.113472
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 2009;94(1):70–77. doi:10.3324/haematol.13574
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205–1213. doi:10.1182/blood-2008-01-135160
   PubMed Web of Science ®Google Scholar
• Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182(7):4415–4422. doi:10.4049/jimmunol.0713732
   PubMed Web of Science ®Google Scholar
• Citterio G, Reni M, Gatta G, et al. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017;113:97–110. doi:10.1016/j.critrevonc.2017.03.019
   PubMed Web of Science ®Google Scholar
• Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193–2201. doi:10.1182/blood-2015-02-629600
   PubMed Web of Science ®Google Scholar
• Al-Khateeb E, Abbas MA, Khader MB, et al. Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis. Int J Biol Markers. 2023;38(1):53–60. doi:10.1177/03936155221149749
   PubMed Web of Science ®Google Scholar
• Hayano A, Komohara Y, Takashima Y, et al. Programmed cell death ligand 1 expression in primary central nervous system lymphomas: a clinicopathological study. Anticancer Res. 2017;37(10):5655–5666.
   PubMed Web of Science ®Google Scholar
• Furuse M, Kuwabara H, Ikeda N, et al. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer. 2020;20(1):277. doi:10.1186/s12885-020-06755-y
   PubMed Web of Science ®Google Scholar
• Parkhi M, Chatterjee D, Bal A, et al. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population. APMIS. 2022;130(2):82–94. doi:10.1111/apm.13195
   PubMed Web of Science ®Google Scholar
• Kim HR, Ha SJ, Hong MH, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6(1):36956. doi:10.1038/srep36956
   PubMedGoogle Scholar